Experimental gene therapies like AMT‑130 lower toxic huntingtin protein and significantly slow Huntington’s disease, offering ...
Add Yahoo as a preferred source to see more of our stories on Google. MRI of a brain with Huntington's Disease. (Zephyr/Science Source) Every week neurologist Victor Sung sees people with Huntington’s ...
Huntington's disease (HD) has long been impossible to cure, but new research is finally giving fresh hope. HD is a ...
Medically reviewed by Smita Patel, DO Key Takeaways Huntington’s disease causes unintentional movements, as well as ...
New treatments and clinical trials are offering renewed optimism to families affected by the degenerative neurological condition.
Verywell Health on MSN

What causes Huntington’s disease?

Medically reviewed by Brigid Dwyer, MD Key Takeaways Huntington’s disease is a genetic condition that is inherited in an ...
Nearly 150 people gathered at Waterfront Park on Sunday for the Huntington’s Disease Society of America’s Team Hope Walk, uniting families, advocates and supporters. IMPORTANCE. ACCORDING TO THE ...
UCL and uniQure report the first treatment to slow Huntington’s disease with gene therapy AMT-130. High-dose patients had 75% less progression over three years compared with standard care. uniQure ...
Huntington's disease diagnosis is confirmed with a genetic test. A clinical history and medical evaluation are used to define symptom onset. Disease staging and surveillance for complications are ...
ST. LOUIS — Scientists may have reached a breakthrough in the fight against Huntington’s disease, a rare and fatal inherited brain disorder with no cure. For the first time, a gene therapy has been ...
Huntington's Disease is a fatal genetic disease that breaks down the mind and body, and there is no cure. About 41,000 people live with this debilitating disease. Next Saturday you can join families ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the submission of its clinical trial application (CTA) for Study SRP-1005-101, ...